CCAIM Announces Partnership with Takeda to Advance AI’s Impact in Pharmaceutical R&D
Cambridge, 15 June 2026 – The Cambridge Centre for AI in Medicine (CCAIM) today announced a partnership with Takeda to support the advancement AI across industry’s R&D value chain, including discovery research, pharmaceutical sciences, and clinical development. Takeda joins a growing network of CCAIM pharmaceutical company partners seeking to improve the future of medicine through artificial intelligence and machine learning.
AI is entering a new era. Beyond analysing existing data, the next generation of AI has the potential to accelerate scientific discovery and support decision-making across healthcare and biomedicine. This could mean improving patient stratification, designing more efficient clinical trials, identifying promising therapeutic targets, and reducing the risks and costs associated with drug development. Realising this potential requires deep collaboration between world-leading AI researchers, clinicians, biomedical scientists, and industry innovators.
Through this partnership, CCAIM and Takeda aim to explore how cutting-edge advances in machine learning can address some of the most important challenges across medicine and healthcare.
“Takeda is embedding AI across our R&D value chain to help deliver life-transforming treatments faster and with greater confidence,” said Justine Rochon, Head of R&D Data & Quantitative Sciences at Takeda. “AI will play an increasingly important role in pharmaceutical R&D and realizing its transformative potential will require strong multistakeholder collaboration. We are excited to partner with CCAIM as we work together to explore practical solutions for the complex problems that matter most and advance meaningful innovation for patients.”
“We are delighted to welcome Takeda to CCAIM. This is an incredibly exciting time for AI in medicine. By bringing together expertise across AI, biology, clinical science and drug development, we have an opportunity not only to improve existing processes, but to fundamentally rethink how we discover, develop and deliver better treatments for patients,” said Professor Mihaela van der Schaar, Director of CCAIM.
The partnership reflects CCAIM’s mission to ensure that advances in AI are driven by real-world medical challenges and translated into meaningful impact for scientists, clinicians and patients. Together with its partners, CCAIM aims to push the boundaries of AI in medicine, advancing research that can accelerate scientific discovery, support therapeutic development, and improve patient outcomes.
About CCAIM
The Cambridge Centre for AI in Medicine (CCAIM) is a leading research institution as part of the University of Cambridge, dedicated to the development and application of artificial intelligence in the field of medicine. CCAIM aims to revolutionise healthcare through innovative research, education, and collaboration with industry collaborators.